Patients With Ovarian Cancer Likely to Respond to Rucaparib Using Tumor Genetic Analysis


Robert L. Coleman, MD, FACOG, FACS, professor, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, vice chair, Clinical Research, The University of Texas MD Anderson Cancer Center, discusses the results of the ARIEL2 trial, a phase II study to identify patients with ovarian cancer likely to respond to rucaparib using tumor genetic analysis.

Related Videos
Related Content